AL-S Pharma AG
PrivateLast Round
VC Round
Dec 7, 2016
Company Overview
AL-S Pharma AG operates in Healthcare & Life Sciences and is based in Schlieren. Its latest recorded funding round was a VC Round in December 2016.
AL-S Pharma AG is a clinical-stage biotechnology company developing AP-101, an antibody therapeutic for the treatment of amyotrophic lateral sclerosis (ALS).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AL-S Pharma AG Comparables
Compare AL-S Pharma AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Axoltis Pharma | 78% | |
| Prilenia Therapeutics | 78% | |
| QurAlis | 77% |
For institutional investors. Book with your work email.
AL-S Pharma AG Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
AL-S Pharma AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TVM Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 7, 2016
Raised capital from TVM Capital and Neurimmune AG.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 29, 2026
AL-S Pharma AG attends the 2026 Network of Excellence for ALS meeting in Florida and online in Oct '26, where chief medical officer Angela Genge shares AP-101 data in an oral presentation.
- attends_eventOct 26, 2026
AL-S Pharma AG attends the 2026 NEALS Annual Meeting in Florida in Oct '26, where it reports new AP-101 Phase 2 weight data and outlines a planned Phase 3 ALS trial.
- hiresOct 14, 2026
AL-S Pharma AG appoints Harry Welten as CEO in Switzerland on Oct 28th '26, tasking him with executing the AP-101 Phase 3 program and securing financing and strategic partnerships.
For institutional investors. Book with your work email.
AL-S Pharma AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AL-S Pharma AG's valuation, stock price, and market status.
Is AL-S Pharma AG a public or private company?
AL-S Pharma AG is a private company.
What is the current stock price of AL-S Pharma AG?
AL-S Pharma AG is a private company, so its shares have no public market price. Caplight tracks AL-S Pharma AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AL-S Pharma AG worth (valuation)?
Valuation information for AL-S Pharma AG is not publicly available.
Can I buy AL-S Pharma AG stock?
AL-S Pharma AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AL-S Pharma AG's last funding round?
AL-S Pharma AG's most recent funding round was VC Round on December 7, 2016.
Who are the main investors in AL-S Pharma AG?
Key investors in AL-S Pharma AG include TVM Capital.
Will AL-S Pharma AG IPO soon?
No public IPO plans have been announced for AL-S Pharma AG.
How can I track AL-S Pharma AG secondary market activity?
Caplight tracks bids, offers, and trades in AL-S Pharma AG's shares on secondary markets.